Drug Profile
Muscle-derived autologous stem cell therapy - U.S. Stem Cell
Alternative Names: Implanted autologous skeletal myoblasts - U.S. Stem Cell; Myoblast-derived autologous stem cell therapy - U.S. Stem Cell; MyoCell; MyoCell II; MyoCell SDF-1; Second-generation MyoCell SDF-1 myogenic cell composition - U.S. Stem CellLatest Information Update: 27 Nov 2017
Price :
$50
*
At a glance
- Originator Bioheart
- Developer AnC Bio; Bioheart; Magnum Cell Therapies; Revita Life Sciences; U.S. Stem Cell
- Class Cardiovascular therapies; Cell therapies; Heart failure therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Heart failure
Highest Development Phases
- Marketed Heart failure
- No development reported Myocardial infarction
Most Recent Events
- 21 Nov 2017 Muscle-derived autologous stem cell therapy - U.S. Stem Cell is available for licensing as of 21 Nov 2017. http://us-stemcell.com/
- 21 Nov 2017 U.S. Stem Cell seeks Regenerative Medicine Advance Therapy (RMAT) designation for Heart failure
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Heart-failure in Uganda (Intracardiac)